Allergy Therapeutics Takes First Steps Into Broader Vaccine Field
Licensing Agreement Signed With Saiba And DeepVax
Allergy Therapeutics is keen to extend its early R&D pipeline into non-allergy areas through extending its tie-up with Saiba and DeepVax on their virus-like particle technology.
You may also be interested in...
Hanmi is accelerating development of a plant-derived COVID-19 vaccine with Bioapp after successful early, the forming part of the leading South Korean pharma group’s post-pandemic business vision, which includes 'green biotech'.
An ultra-fast-acting allergy immunotherapy to induce tolerance to house dust mites is being sought in a collaboration between two Swiss biotechs, Anergis and Virometix.
Clinical studies of grass allergy and peanut allergy vaccines are expected to start this year, as the UK specialty company plots its entry into the US.